- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01185054
Is Electrolyte Maintenance Solution Required in Low-Risk Children With Gastroenteritis?
April 16, 2018 updated by: Stephen Freedman, The Hospital for Sick Children
The objective of this study is to clarify the current standard of care by determining if Electrolyte Maintenance Solution (EMS) is truly the optimal fluid to be used in low-risk children who present to an Emergency Department (ED) with < 72 hours of vomiting or diarrhea.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Gastroenteritis remains a major cause of morbidity amongst Canadian children.
The primary treatment focus revolves around the use of Oral Rehydration Therapy (ORT) to treat dehydration and replace intravascular volume.
Since diarrheal disease in Canadian children usually results in mild dehydration and minimal sodium losses, the use of low sodium Electrolyte Maintenance Solutions (EMS) has become the standard of care.
However, given that North American children infrequently develop severe dehydration, it is unclear if the routine use of EMS is justified.
When pediatricians directly dispense EMS, 16 children need to be treated to prevent 1 unscheduled office visit, however the upper bound of the 95% confidence interval is an astounding 508 patients.
In addition, EMS is considered by some to be prohibitively expensive, with 15% of pediatricians believing it to be too expensive for their patients to purchase.
An additional 40% report that taste is a major barrier to consumption.
As a result, oral fluid replenishment is often underutilized and IV rehydration employed instead.
Our goal is to provide evidence to guide the selection of the optimal ORT fluids in low-risk children, thus increasing its use, enhancing its success, and reducing the reliance on intravenous rehydration.
We hypothesize that the strict adherence to EMS use in low-risk children may actually be counterproductive by resulting in reduced fluid intake and potentially increasing the use of intravenous rehydration.
Study Type
Interventional
Enrollment (Actual)
624
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 5 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥3 episodes of vomiting or diarrhea in preceding 24 hours
- Duration of illness less than 96 hours
- Age 6 - 60 months
- Clinical suspicion of acute intestinal infectious process
- Weight ≥ 8 kg
- Clinical dehydration score < 5
- Capillary refill < 2 seconds
- Absence of bulging fontanelle
- Absence of bilious vomiting
- Absence of blood in diarrhea/emesis
- Absence of abdominal pain (if present reported as periumbilical in location)
- Absence of abdominal distention
- Absence of acute disease currently requiring treatment
- Absence of co-existing diseases (prematurity, cardiac, renal, neurological, metabolic, endocrine, immunodeficiency, trauma or history of ingestion)
Exclusion Criteria:
- Known gastrointestinal diseases (ie. inflammatory bowel disease, celiac) or any other underlying disease process that might place the child at an increased risk of treatment failure.
- Age < 6 months
- Weight < 8 kg
- If premature, corrected gestational age < 30 weeks
- Presence of hematochezia
- Responsible physician judges the child requires immediate intravenous rehydration
- English language is so limited that consent and/or follow-up is not possible.
- Non-Ontario resident [Canadian Institute for Health Information (CIHI) follow-up data will not be available]
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Fluids as Tolerated (FAT) Group
The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
|
For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given.
If the child does not like the solution another fluid can be used.
|
|
ACTIVE_COMPARATOR: Electrolyte Maintenance Solution (EMS)
The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
|
For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given.
If the child does not like the solution another electrolyte maintenance fluid can be used.
Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of children experiencing a treatment failure
Time Frame: Within 7 days of enrolment
|
This outcome will be deemed to have occurred if any of the following occur:
|
Within 7 days of enrolment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Weight Change
Time Frame: 72-84 hours after enrolment
|
72-84 hours after enrolment
|
|
Proportion of Subjects Receiving Intravenous Rehydration
Time Frame: 7 days
|
7 days
|
|
Proportion of Subjects Requiring Hospitalization
Time Frame: 7 days
|
7 days
|
|
Frequency of diarrhea and vomiting episodes
Time Frame: 7 days
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stephen Freedman, MD, The Hospital for Sick Children, Toronto Canada
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (ACTUAL)
May 1, 2015
Study Completion (ACTUAL)
May 1, 2015
Study Registration Dates
First Submitted
August 18, 2010
First Submitted That Met QC Criteria
August 18, 2010
First Posted (ESTIMATE)
August 19, 2010
Study Record Updates
Last Update Posted (ACTUAL)
April 17, 2018
Last Update Submitted That Met QC Criteria
April 16, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000017642
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastroenteritis
-
GlaxoSmithKlineCompletedRotavirus Gastroenteritis | Nosocomial Rotavirus Gastroenteritis
-
ModernaTX, Inc.Active, not recruitingAcute Gastroenteritis | Norovirus Acute GastroenteritisUnited States, Australia, United Kingdom, Canada, Japan, Panama, Puerto Rico
-
Sinovac Life Sciences Co., Ltd.CompletedRotavirus GastroenteritisChina
-
University Hospital for Infectious Diseases, CroatiaCompletedRotavirus GastroenteritisCroatia
-
National Institute of Allergy and Infectious Diseases...CompletedGastroenteritis NorovirusUnited States
-
Merck Sharp & Dohme LLCCompleted
-
MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.ParexelCompletedRotavirus GastroenteritisBangladesh
-
PATHCenters for Disease Control and Prevention; Noguchi Memorial Institute for... and other collaboratorsCompletedRotavirus GastroenteritisGhana
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisGreece
-
Shantha Biotechnics LimitedCompletedRotavirus GastroenteritisIndia
Clinical Trials on ½ strength apple juice
-
Clinical Nutrition Research Center, Illinois Institute...Completed
-
Clinical Research Center Kiel GmbHNofimaCompleted
-
PepsiCo Global R&DCompletedDigestive HealthUnited States
-
Maastricht University Medical CenterCompleted
-
Hopital FochCompleted
-
PepsiCo Global R&DCompletedGlycemic ResponseUnited States
-
Universidade Federal de Santa CatarinaCompletedOxidative Stress
-
University of MinnesotaCompletedCardiovascular DiseaseUnited States
-
Khon Kaen UniversityCompleted